Amgen Inc. — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. Amgen is a biotechnology company focused on human therapeutics and reports one business segment. The filing also provides unaudited fourth-quarter results.
Financial performance and position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $20.063 billion | $18.676 billion | +7% |
| Product sales | $19.327 billion | $18.192 billion | +6% |
| Operating income | $6.191 billion | $5.867 billion | +6% |
| Net income | $5.158 billion | $5.081 billion | +2% |
| Diluted EPS | $6.70 | $6.64 | +1% |
| Operating margin | 30.8% | 31.4% | Down 0.6 percentage points |
| Net cash from operations | $8.555 billion | $6.291 billion | +$2.264 billion |
Cost of sales was $4.422 billion, or 22.0% of revenue, versus $3.346 billion, or 17.9%, in 2013. The increase reflected, in part, $642 million of additional non-cash amortization of acquired Onyx intangible assets, $104 million of restructuring-related impairment and accelerated depreciation, and a $99 million Roche contract termination charge. R&D expense rose 5% to $4.297 billion; SG&A declined 9% to $4.699 billion, principally after the ENBREL co-promotion term expired.
Fourth quarter: Product sales were $5.174 billion versus $4.799 billion a year earlier; net income was $1.294 billion versus $1.021 billion; diluted EPS was $1.68 versus $1.33.
Liquidity and debt: Cash, cash equivalents and marketable securities totaled $27.026 billion at year-end, up from $19.401 billion; current assets were $34.713 billion and current liabilities $7.008 billion. Total debt was $30.715 billion, down from $32.128 billion. Operating cash flow funded capital needs and shareholder returns; capital expenditures were $718 million. About $25.7 billion of cash and investments was generated outside the United States and intended to remain invested abroad. The company reported no material off-balance-sheet arrangements and compliance with applicable debt covenants.
The effective tax rate was 7.6%, compared with 3.5% in 2013; the filing attributes the increase mainly to prior-year tax benefits, partly offset by favorable tax effects from income mix, acquisition expenses and restructuring costs. Approximately $29.3 billion of cumulative foreign earnings were intended to remain abroad; estimated additional U.S. tax on repatriation was $10.5 billion.
Material changes versus 2013
- U.S. product sales grew 5% to $14.732 billion; rest-of-world product sales grew 11% to $4.595 billion.
- Prolia sales increased 38% to $1.030 billion and XGEVA sales increased 20% to $1.221 billion. Other product sales rose 33%, including a full year of Kyprolis sales following the Onyx acquisition.
- Combined Neulasta/NEUPOGEN sales declined 1% to $5.755 billion. NEUPOGEN sales fell 17% globally; U.S. sales were affected by a $155 million government stockpile order in 2013 and lower unit demand.
- Operating expenses increased 8%, led by higher cost of sales and restructuring charges. Net income grew more slowly than revenue, reflecting higher costs and a higher effective tax rate.
- Operating cash flow increased to $8.555 billion, while total debt declined by $1.413 billion.
Outlook, commentary, risks and unusual items
- Management highlighted pipeline launches, biosimilars, geographic expansion, manufacturing productivity and shareholder returns as strategic priorities. The filing does not provide a clear numerical revenue or EPS forecast.
- Management estimated 2015 capital spending of approximately $800 million. A restructuring plan calls for 3,500–4,000 staff reductions by the end of 2015, facility closures and a smaller Thousand Oaks footprint. Estimated pretax charges are $935 million–$1.035 billion; $558 million was incurred in 2014.
- Pipeline milestones included FDA accelerated approval of BLINCYTO for a specific relapsed/refractory leukemia indication and FDA review of evolocumab for high cholesterol. Continued BLINCYTO approval may depend on confirming clinical benefit. The filing also reports positive phase 3 results for certain candidates, alongside failed or discontinued programs, including rilotumumab studies and trebananib development in recurrent ovarian cancer.
- Key risks include biosimilar competition and upcoming patent expirations, pricing and reimbursement pressure, dependence on a small number of wholesalers and dialysis customers, manufacturing and single-source supplier risks, regulatory and clinical-trial uncertainty, and foreign-exchange and tax exposure.
- Amgen disclosed ongoing litigation and other proceedings, including biosimilar patent disputes and shareholder cases. For the described matters, the filing generally says outcomes are uncertain and a loss range cannot be estimated or is not material; an adverse outcome could nevertheless materially affect results, financial position or cash flows.
- Other notable items: Amgen paid $1.851 billion in dividends and repurchased $153 million of shares in 2014. The board declared a $0.79-per-share dividend payable in March 2015. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Progress, approval timing and commercial uptake for evolocumab, Kyprolis, talimogene laherparepvec, brodalumab and other late-stage candidates.
- Actual 2015 restructuring charges, savings and execution against the planned workforce and facility reductions.
- Revenue, pricing and market-share effects from biosimilar entry and patent expirations, especially for NEUPOGEN, Neulasta and EPOGEN.
- Debt repayment and capital allocation plans, including dividends and share repurchases, alongside the company’s substantial foreign-held cash and potential repatriation tax.
- Developments in litigation, product safety, manufacturing reliability, reimbursement and customer concentration.